ALTIMMUNE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ALTIMMUNE, INC. (ALT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.22 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-12
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 607.65K shares, a 440.13% increase year-over-year.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 1.61M shares, a 12.74% decline year-over-year.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 2.80M shares, a 881.12% increase year-over-year.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 717.20K shares, a 181.48% increase year-over-year.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 5.47M shares, a 159.61% increase from fiscal 2024.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.11M shares, a 19.68% increase from fiscal 2023.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.76M shares, a 19.45% increase from fiscal 2022.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.47M shares, a 20.21% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 607.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 2.22M shares 10-Q · filed 2026-08-12 | 5.01M shares derived: sum of 3 quarters · filed 2026-08-12 | 5.73M shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 1.61M shares 10-Q · filed 2026-05-13 | 4.40M shares derived: sum of 2 quarters · filed 2026-05-13 | 5.12M shares derived: sum of 3 quarters · filed 2026-05-13 | 5.23M shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 2.80M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | 3.51M shares derived: sum of 2 quarters · filed 2026-03-06 | 3.63M shares derived: sum of 3 quarters · filed 2026-03-06 | 5.47M shares 10-K · filed 2026-03-06 |
| 2025-09-30 | 717.20K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 829.70K shares derived: sum of 2 quarters · filed 2025-11-06 | 2.67M shares 10-Q · filed 2025-11-06 | 2.96M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 112.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 1.95M shares 10-Q · filed 2025-08-12 | 2.24M shares derived: sum of 3 quarters · filed 2025-08-12 | 2.49M shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 1.84M shares 10-Q · filed 2025-05-13 | 2.13M shares derived: sum of 2 quarters · filed 2025-05-13 | 2.38M shares derived: sum of 3 quarters · filed 2025-05-13 | 2.38M shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 285.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 539.80K shares derived: sum of 2 quarters · filed 2025-02-27 | 539.80K shares derived: sum of 3 quarters · filed 2025-02-27 | 2.11M shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 254.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 254.80K shares derived: sum of 2 quarters · filed 2024-11-12 | 1.82M shares 10-Q · filed 2024-11-12 | |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 1.57M shares 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | 1.57M shares 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | 1.76M shares 10-K · filed 2024-03-27 | |||
| 2022-12-31 | 1.47M shares 10-K · filed 2023-02-28 | |||
| 2021-12-31 | 1.23M shares 10-K · filed 2022-03-15 | |||
| 2020-12-31 | 708.00K shares 10-K · filed 2021-02-25 | |||
| 2019-12-31 | 725.00K shares 10-K · filed 2020-03-27 | |||
| 2018-12-31 | 339.62K shares 10-K · filed 2019-04-01 | |||
| 2017-12-31 | 801.93K shares 10-K · filed 2018-04-02 | |||
| 2016-12-31 | 185.33K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | 185.33K shares derived: sum of 2 quarters · filed 2017-03-14 | 385.33K shares derived: sum of 3 quarters · filed 2017-03-14 | 385.33K shares 10-K · filed 2017-03-14 |
| 2016-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | 200.00K shares derived: sum of 2 quarters · filed 2016-11-04 | 200.00K shares 10-Q · filed 2016-11-04 | |
| 2016-06-30 | 200.00K shares 10-Q · filed 2016-08-04 | 200.00K shares 10-Q · filed 2016-08-04 | ||
| 2016-03-31 | 0.00 shares 10-Q · filed 2016-05-09 | |||
| 2015-09-30 | 100.00K shares 10-Q · filed 2016-11-04 | 100.00K shares derived: sum of 2 quarters · filed 2016-11-04 | 112.00K shares 10-Q · filed 2016-11-04 | |
| 2015-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | 12.00K shares 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | 12.00K shares 10-Q · filed 2016-05-09 | |||
| 2013-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | 145.00K shares derived: sum of 2 quarters · filed 2013-11-07 | 205.00K shares 10-Q · filed 2013-11-07 | 856.19K shares derived: sum of 4 quarters · filed 2013-11-07 |
| 2013-06-30 | 145.00K shares 10-Q · filed 2013-08-08 | 205.00K shares 10-Q · filed 2013-08-08 | 856.19K shares derived: sum of 3 quarters · filed 2013-08-08 | 856.19K shares derived: sum of 4 quarters · filed 2013-11-07 |
| 2013-03-31 | 60.00K shares 10-Q · filed 2013-05-08 | 711.19K shares derived: sum of 2 quarters · filed 2013-05-08 | 711.19K shares derived: sum of 3 quarters · filed 2013-11-07 | 896.19K shares derived: sum of 4 quarters · filed 2013-11-07 |
| 2012-12-31 | 651.19K shares derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-14 | 651.19K shares derived: sum of 2 quarters · filed 2013-11-07 | 836.19K shares derived: sum of 3 quarters · filed 2013-11-07 | 852.14K shares 10-K · filed 2013-03-14 |
| 2012-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | 185.00K shares derived: sum of 2 quarters · filed 2013-11-07 | 200.95K shares 10-Q · filed 2013-11-07 | |
| 2012-06-30 | 185.00K shares 10-Q · filed 2013-08-08 | 200.95K shares 10-Q · filed 2013-08-08 | ||
| 2012-03-31 | 15.95K shares 10-Q · filed 2013-05-08 | |||
| 2011-12-31 | 1.93M shares 10-K · filed 2013-03-14 | |||
| 2010-12-31 | 2.72M shares 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |